Orchid Pharma Intrinsic Value
Orchid Pharma intrinsic value. Orchid Pharma (ORCHPHARMA) median intrinsic value is ₹386.36 from 9 valuation models (range ₹290–₹521), vs current price ₹965.90 — -60.0% downside (Trading Above Calculated Value), margin of safety -100.0%. Read Orchid Pharma dividend payments for the complete payout history and dividend yield track record.
ORCHPHARMA Valuation Methods Summary — DCF, Graham Number & P/E
Orchid Pharma intrinsic value across 9 models vs current price ₹965.90 — upside/downside and value range per method. For current market price and key ratios, visit ORCHPHARMA stock price BSE.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹379.28 | ₹303.42 - ₹455.14 | -60.7% | EPS: ₹17.24, Sector P/E: 22x |
| Book Value Method | asset | ₹521.33 | ₹469.20 - ₹573.46 | -46.0% | Book Value/Share: ₹260.67, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹501.33 | ₹451.20 - ₹551.46 | -48.1% | Revenue/Share: ₹250.67, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹386.36 | ₹347.72 - ₹425.00 | -60.0% | EBITDA: ₹152.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹386.36 | ₹309.09 - ₹463.63 | -60.0% | CF Growth: 7.9%, Discount: 15% |
| PEG Ratio Method | growth | ₹289.77 | ₹260.79 - ₹318.75 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹289.77 | ₹260.79 - ₹318.75 | -70.0% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹482.95 | ₹434.65 - ₹531.25 | -50.0% | ROE: 6.6%, P/E Multiple: 10x |
| Graham Defensive Method | conservative | ₹317.98 | ₹286.18 - ₹349.78 | -67.1% | EPS: ₹17.24, BVPS: ₹260.67 |
ORCHPHARMA Intrinsic Value vs Market Price — All Valuation Models
Orchid Pharma fair value range ₹290–₹521 vs current market price ₹965.90 across 9 valuation models. Compare with ORCHPHARMA fair value estimate to assess whether the stock is under or overvalued.
ORCHPHARMA Intrinsic Value Analysis — Undervalued or Overvalued?
Orchid Pharma median intrinsic value ₹386.36, current price ₹965.90 — Trading Above Calculated Value by 60.0%, margin of safety -100.0%.
What is the intrinsic value of ORCHPHARMA?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Orchid Pharma (ORCHPHARMA) is ₹386.36 (median value). With the current market price of ₹965.90, this represents a -60.0% variance from our estimated fair value.
The valuation range spans from ₹289.77 to ₹521.33, indicating ₹289.77 - ₹521.33.
Is ORCHPHARMA undervalued or overvalued?
Based on our multi-method analysis, Orchid Pharma (ORCHPHARMA) appears to be trading above calculated value by approximately 60.0%.
ORCHPHARMA Financial Health — Key Ratios vs Industry Benchmarks
Orchid Pharma financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 4.58 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 6.6% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
| Operating Margin | 8.0% | Industry Standard: 20%+ | Below 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.67x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
ORCHPHARMA Cash Flow Quality — Operating & Free Cash Flow
Orchid Pharma operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2026 | ₹126 Cr | ₹-13 Cr | Positive Operating Cash Flow | 6/10 |
| March 2025 | ₹51 Cr | ₹33 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹126 Cr | ₹-30 Cr | Positive Operating Cash Flow | 6/10 |
| March 2023 | ₹18 Cr | ₹3 Cr | Positive Free Cash Flow | 7/10 |
| March 2022 | ₹93 Cr | ₹93 Cr | Positive Free Cash Flow | 8/10 |